
GENERALIFE BUILDS A EUROPEAN LEADER IN ASSISTED REPRODUCTION

GeneraLife



23rd November 2020 – GeneraLife (the “Company”), a company owned by an independently-managed investment subsidiary of Investindustrial, successfully continues its consolidation strategy in the highly fragmented European fertility industry. GeneraLife (www.generaLife.com) is one of the largest groups of fertility clinics in Europe, which has been established through six acquisitions across four countries (Spain, Italy, Czech Republic and Sweden) in the past 18 months.

Today, the Company has more than €40 million in revenues, comprises twelve clinics as well as several satellite and consultation centres, carries out more than 15,000 treatments yearly and employs more than 350 doctors and other healthcare professionals. GeneraLife is led by CEO Marcos Bueso and Scientific Directors Laura Rienzi and Filippo Maria Ubaldi, two of the most internationally recognised experts in assisted reproduction.

Following the initial acquisition of Ginefiv (Spain) in April 2019 and FertiCare (Czech Republic) in August 2019, the Company has been particularly active during 2020 in the execution of its pan-European build-up strategy with the entry in Italy and Sweden.

In Italy, Europe’s fastest growing market, GeneraLife established the largest group of private fertility clinics:

- In July 2020, the Company completed the acquisition of Genera, a leading group of fertility clinics with operations in Rome (headquarters with a training centre), Perugia, Vicenza, and Naples.
- In August 2020, GeneraLife acquired Livet. Founded in 1997, Livet is the leading private fertility clinic in Turin.
- In October 2020, the Company completed the acquisition of Demetra. Founded in 1980, Demetra is one of the largest fertility clinics in Tuscany with operations in Florence and Grosseto.

In Sweden, GeneralLife acquired Carl von Linnékliniken in October 2020. Founded in 1990 and based in Uppsala, Carl von Linnékliniken is the country's single largest clinic for private fertility treatments.

The UN Sustainable Development Goals (in particular, SDG 3.7) are at the core of GeneralLife to ensure universal access to sexual and reproductive healthcare services. The Company has been progressing on their sustainability commitments and is on track to complete its sustainability strategy and goals for the next five years.

Infertility has been defined by the World Health Organisation as a “*global public health issue*” and it affects a growing population due to a range of social and medical factors. With a strong focus on best-in-class research, scientific protocols and patient care, the expansion of GeneralLife represents a significant development for the industry and for the thousands of patients which benefit from fertility treatments every year.

“GeneralLife has combined decades of expertise at a medical and scientific level with the support and leadership of a seasoned management team, and its creation represents a historical milestone in the European assisted reproduction field”, says Marcos Bueso, CEO of GeneralLife. “The company has a concentration of talent and knowledge on reproductive medicine that cannot be found elsewhere in Europe. We are committed to tailoring the most suitable treatment for each patient’s needs, using the best technology, procedures and techniques available, and continuously seeking to maximise success rates”.

“The creation of GeneralLife, which enhances proximity to patients with the guarantee of a common treatment quality, represents an important event for all European patients”, underline Filippo Maria Ubaldi and Laura Rienzi, Scientific Directors of GeneralLife. “Through the use of best-in-class technologies and as a result of our continuous scientific research, we can guarantee high-quality assistance and maximum safety for patients. The range of treatments is the most complete that can be offered, subject to the strictest quality controls and validated protocols. Transparency, honesty and science are part of our DNA, and the patient is always at the centre of our decision-making processes”.

GeneralLife is expected to continue growing in the upcoming years both organically and through additional acquisitions, consolidating a fragmented industry with a strong potential for scientifically driven value creation for all stakeholders.

-ENDS-

About Investindustrial

Investindustrial is a leading European group of independently managed investment, holding and advisory companies with €11 billion of raised fund capital. Investindustrial has a 30-year history of providing mid-market companies capital, industrial expertise, operational focus and global platforms to accelerate value creation and international expansion. Certain companies of the Investindustrial group are authorized by, and subject to regulatory supervision of the FCA in the United Kingdom and the CSSF in Luxembourg. Investindustrial's investment companies act independently from each other and each Investindustrial fund. Additional information is available at www.investindustrial.com.

About GeneralLife

GeneralLife is one of the largest groups of fertility clinics in Europe, which has been created through six acquisitions since April 2019. The group comprises twelve clinics across four countries: Spain (Madrid and Barcelona), Italy (Rome, Turin, Florence, Naples, Vicenza, Perugia and Grosseto), Czech Republic (Prague, Karlovy Vary and Znojmo) and Sweden (Uppsala). GeneralLife carries out more than 15,000 treatments yearly and employs more than 350 doctors and other healthcare professionals. Additional information is available at www.generalife.com.

PRESS RELEASE



For further information please contact:

Maitland/AMO

David Sturken, Jonathan Cook
Tel +44 (0)20 7379 5151
Email: dsturken@maitland.co.uk
Email: jcook@maitland.co.uk

Investindustrial

Carl Nauckhoff
Senior Principal & Head of Investor Relations
Tel +44 (0) 207 664 2138
Email: cnauckhoff@investindustrial.com

Investindustrial Advisors Limited is registered in England with its registered address at 16 Palace Street, London SW1E 5JD and company number 01316019. Investindustrial Advisors Limited is authorised and regulated by the United Kingdom's Financial Conduct Authority as an Alternative Investment Fund Manager (Financial Services Register number: 170924).